194 related articles for article (PubMed ID: 36077742)
1. Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG).
Lyu C; Wang L; Stadlbauer B; Noessner E; Buchner A; Pohla H
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077742
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract][Full Text] [Related]
3. The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review.
Chaudhuri R; Samanta A; Saha P; Ghosh S; Sinha D
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38243984
[TBL] [Abstract][Full Text] [Related]
4. EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis.
Sun C; Zhao C; Li S; Wang J; Zhou Q; Sun J; Ding Q; Liu M; Ding G
J Cancer; 2018; 9(20):3787-3796. PubMed ID: 30405850
[No Abstract] [Full Text] [Related]
5. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
6. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
Ying L; Yan F; Williams BR; Xu P; Li X; Zhao Y; Hu Y; Wang Y; Xu D; Dai J
Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):58-67. PubMed ID: 28925507
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation.
Wubetu GY; Shimada M; Morine Y; Ikemoto T; Ishikawa D; Iwahashi S; Yamada S; Saito Y; Arakawa Y; Imura S
J Gastroenterol Hepatol; 2016 Jan; 31(1):256-64. PubMed ID: 26241688
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
Toden S; Tran HM; Tovar-Camargo OA; Okugawa Y; Goel A
Oncotarget; 2016 Mar; 7(13):16158-71. PubMed ID: 26930714
[TBL] [Abstract][Full Text] [Related]
9. EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.
Xu ZQ; Zhang L; Gao BS; Wan YG; Zhang XH; Chen B; Wang YT; Sun N; Fu YW
Clin Transl Oncol; 2015 Jan; 17(1):41-9. PubMed ID: 24986100
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin gallate inhibits the proliferation and induces apoptosis of multiple myeloma cells via inactivating EZH2.
Zhou CG; Hui LM; Luo JM
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):2093-2098. PubMed ID: 29687868
[TBL] [Abstract][Full Text] [Related]
11. Human cancer stem cells are a target for cancer prevention using (-)-epigallocatechin gallate.
Fujiki H; Sueoka E; Rawangkan A; Suganuma M
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2401-2412. PubMed ID: 28942499
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway.
Lee SH; Nam HJ; Kang HJ; Kwon HW; Lim YC
Eur J Cancer; 2013 Oct; 49(15):3210-8. PubMed ID: 23876835
[TBL] [Abstract][Full Text] [Related]
13. High kinesin family member 11 expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Jin Q; Dai Y; Wang Y; Zhang S; Liu G
J Clin Pathol; 2019 May; 72(5):354-362. PubMed ID: 30819726
[TBL] [Abstract][Full Text] [Related]
14. Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines.
Lin CH; Shen YA; Hung PH; Yu YB; Chen YJ
BMC Complement Altern Med; 2012 Oct; 12():201. PubMed ID: 23110507
[TBL] [Abstract][Full Text] [Related]
15. Wnt/β-catenin pathway mediates (-)-Epigallocatechin-3-gallate (EGCG) inhibition of lung cancer stem cells.
Zhu J; Jiang Y; Yang X; Wang S; Xie C; Li X; Li Y; Chen Y; Wang X; Meng Y; Zhu M; Wu R; Huang C; Ma X; Geng S; Wu J; Zhong C
Biochem Biophys Res Commun; 2017 Jan; 482(1):15-21. PubMed ID: 27836540
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin-3-gallate inhibits nasopharyngeal cancer stem cell self-renewal and migration and reverses the epithelial-mesenchymal transition via NF-κB p65 inactivation.
Li YJ; Wu SL; Lu SM; Chen F; Guo Y; Gan SM; Shi YL; Liu S; Li SL
Tumour Biol; 2015 Apr; 36(4):2747-61. PubMed ID: 25487615
[TBL] [Abstract][Full Text] [Related]
17. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling.
Chung SS; Vadgama JV
Anticancer Res; 2015 Jan; 35(1):39-46. PubMed ID: 25550533
[TBL] [Abstract][Full Text] [Related]
18. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin-3-gallate inhibits migration and invasion of human renal carcinoma cells by downregulating matrix metalloproteinase-2 and matrix metalloproteinase-9.
Chen SJ; Yao XD; Peng BO; Xu YF; Wang GC; Huang J; Liu M; Zheng JH
Exp Ther Med; 2016 Apr; 11(4):1243-1248. PubMed ID: 27073430
[TBL] [Abstract][Full Text] [Related]
20. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p.
Wang L; Yang G; Zhao D; Wang J; Bai Y; Peng Q; Wang H; Fang R; Chen G; Wang Z; Wang K; Li G; Yang Y; Wang Z; Guo P; Peng L; Hou D; Xu W
Mol Cancer; 2019 Apr; 18(1):86. PubMed ID: 30975145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
